Sana’s Cell Therapy Sustains Insulin Production Through 14 Months in a T1D Patient
Sana Biotechnology is looking to start clinical development for its type 1 diabetes therapy SC451 this year.
Sana’s Cell Therapy Sustains Insulin Production Through 14 Months in a T1D Patient Read More »
